drugset / Trial / NCT00676026
Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women
Non-randomizedSingle-groupSingle-blindOther
Summary
The goal of this series of challenge studies is to examine the impact of menstrual cycle phase on cortical GABA response to administration of agents with either direct (benzodiazepines) or indirect (progesterone, fluoxetine) GABA modulating properties. While the impact of these agents on cortical GABA levels in women with premenstrual dysphoric disorder (PMDD) is of interest, this study is designed primarily for those women without a psychiatric illness.
Timeline
- Start
- 2005-05
- Primary completion
- 2009-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluoxetine | Small molecule | 20 mg | Oral |
| Subject | Progesterone | Other / unclassified | 800 mg | Oral |
| Subject | Zolpidem | Small molecule | 10 mg | Oral |
Indications
No indication recorded.